Fedratinib
- Generic Name
- Fedratinib
- Brand Names
- Inrebic
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N6O3S
- CAS Number
- 936091-26-8
- Unique Ingredient Identifier
- 6L1XP550I6
Overview
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Background
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Indication
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Associated Conditions
- Secondary Myelofibrosis
- Primary Myelofibrosis (PMF)
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.